scholarly journals Expression of Peroxisome Proliferator-Activated Receptor Gamma in Salivary Duct Carcinoma: Immunohistochemical Analysis of 15 Cases

2003 ◽  
Vol 16 (12) ◽  
pp. 1218-1223 ◽  
Author(s):  
P. Mukunyadzi
Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1312
Author(s):  
Shih-Lung Chen ◽  
Chi-Ju Yeh ◽  
Kai-Chieh Chan

Background: Salivary duct carcinoma (SDC) is a rare aggressive tumor. Most tumors are not confined to the salivary ducts; rather, they invade the major and minor salivary glands. Only a few case reports on such tumors in other primary sites have appeared. Case presentation: A 40-year-old male complained of right hearing loss (a common condition), but we made an extremely rare diagnosis of an SDC in the external auditory canal (EAC). EAC cancers are frequently misdiagnosed. In our patient, the otoscope revealed a smooth, bulging subcutaneous lesion with a non-epithelial defect suggestive of a benign lesion. However, an SDC of the EAC was confirmed through pathological and immunohistochemical analysis. Conclusions: We suggest detailed evaluation of even smooth EAC subcutaneous lesions to avoid erroneous diagnoses. To the best of our knowledge, this is the first report of SDC in the EAC.


2021 ◽  
pp. 343-346
Author(s):  
Tsuyoshi Sato ◽  
Takahiro Maeta ◽  
Ryosuke Abe ◽  
Hiroyuki Yamada ◽  
Kazuyuki Ishida ◽  
...  

Salivary duct carcinoma (SDC) is a rare and highly aggressive malignancy. A 58-year-old man presented with a right-sided submandibular mass and metastatic lesions in the right supraclavicular and inferior internal jugular nodes. He underwent right submandibulectomy and right neck dissection followed by adjuvant chemoradiotherapy. However, relapse occurred in the hilar lymph node and lumbar spine. Although radiotherapy was performed, a second relapse appeared in the hilar lymph nodes and sacral bone. Immunohistochemical analysis revealed negativity for programmed death ligand-1 (PD-L1) in the primary tumor specimen. The patient then received the anti-programmed death-1 (PD-1) antibody nivolumab. His metastatic lesions were completely eliminated after 48 weeks of therapy. This case reveals that anti-PD-1 antibodies are effective even against PD-L1-negative SDC.


2019 ◽  
Author(s):  
W van Boxtel ◽  
S Lütje ◽  
AC van Engen-van Grunsven ◽  
GW Verhaegh ◽  
JA Schalken ◽  
...  

Author(s):  
Kyung Yeon Kim ◽  
Hae Sang Park ◽  
Sung Min Chung ◽  
Han Su Kim

2019 ◽  
Vol 35 (1) ◽  
pp. 13-20
Author(s):  
Yong Ju Lee ◽  
Yoon Woo Koh ◽  
Sun Och Yoon ◽  
Hyang Joo Ryu ◽  
Hye Ryun Kim ◽  
...  

2021 ◽  
Author(s):  
Keisuke Sato ◽  
Mai Matsumura ◽  
Yoko Anzai ◽  
Hiromasa Arai ◽  
Motoki Sekiya ◽  
...  

Head & Neck ◽  
2021 ◽  
Author(s):  
Gustavo Schvartsman ◽  
Diana Bell ◽  
Maria Laura Rubin ◽  
Michael Tetzlaff ◽  
Ehab Hanna ◽  
...  

Cancer ◽  
2005 ◽  
Vol 103 (12) ◽  
pp. 2526-2533 ◽  
Author(s):  
Michael Jaehne ◽  
Kerstin Roeser ◽  
Thorsten Jaekel ◽  
Jan David Schepers ◽  
Natalie Albert ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document